Home
Mail
Search
News
Finance
Sport
TV
Lifestyle
Entertainment
Mobile
Horoscopes
More
Yahoo
Mail
Watchlists
My Portfolios
Market Data
Latest News
Industries
Personal Finance
Currency Convertor
Video
New Zealand markets closed
NZX 50
11,678.68
-3.82
(-0.03%)
NZD/USD
0.6130
-0.0022
(-0.36%)
ALL ORDS
7,935.70
-99.20
(-1.23%)
OIL
80.46
+0.63
(+0.79%)
GOLD
2,346.60
-9.90
(-0.42%)
Ajanta Pharma Limited (AJANTPHARM.BO)
BSE - BSE Real-time price. Currency in INR
Add to watchlist
2,393.90
-25.10
(-1.04%)
At close: 03:46PM IST
Summary
Chart
Statistics
Historical data
Profile
Financials
Analysis
Options
Holders
Sustainability
Show
:
Income statement
Balance sheet
Cash flow
Annual
Quarterly
Income statement
All numbers in thousands
Breakdown
ttm
31/03/2024
31/03/2023
31/03/2022
31/03/2021
31/03/2020
Total revenue
42,087,100
42,087,100
37,426,400
32,841,300
28,452,000
-
Cost of revenue
10,665,700
10,665,700
10,504,000
8,867,200
6,823,900
-
Gross profit
31,421,400
31,421,400
26,922,400
23,974,100
21,628,100
-
Operating expenses
Selling general and administrative
-
-
2,977,800
2,731,600
2,768,100
3,327,200
Total operating expenses
21,056,000
21,056,000
20,209,700
15,855,300
12,705,700
-
Operating income or loss
10,365,400
10,365,400
6,712,700
8,118,800
8,922,400
-
Interest expense
72,100
72,100
58,400
102,000
82,700
-
Income before tax
11,139,300
11,139,300
7,452,500
9,094,800
9,001,800
-
Income tax expense
2,977,600
2,977,600
1,572,700
1,968,000
2,463,100
-
Income from continuing operations
8,161,700
8,161,700
5,879,800
7,126,800
6,538,700
-
Net income
8,161,700
8,161,700
5,879,800
7,126,800
6,538,700
-
Net income available to common shareholders
8,161,700
8,161,700
5,879,800
7,126,800
6,538,700
-
Basic EPS
52.08
64.82
45.89
54.97
50.06
-
Diluted EPS
52.06
64.77
45.89
54.96
50.06
-
Basic average shares
127,009
125,913
128,128
129,658
130,617
-
Diluted average shares
127,052
126,010
128,128
129,663
130,623
-
Data disclaimer
Help
Suggestions
Terms
and
Privacy Policy
Privacy dashboard
About our ads
© 2024 Yahoo. All rights reserved.